Ir al contenido principal

TNF receptor superfamily member 11b

The TNFRSF11B gene provides instructions for making a protein that plays an important role in bone remodeling, a normal process in which old bone is broken down and replaced by new bone. The TNFRSF11B protein is involved in the regulation of specialized cells called osteoclasts, which break down bone tissue during bone remodeling.

Selecciones de videos para Genes
Biblioteca de videos

Normal function

The TNFRSF11B gene provides instructions for making a protein that plays an important role in bone remodeling, a normal process in which old bone is broken down and replaced by new bone. The TNFRSF11B protein is involved in the regulation of specialized cells called osteoclasts, which break down bone tissue during bone remodeling.

The TNFRSF11B protein belongs to a larger family of receptor proteins. Other proteins, called ligands, can fit into specific sites on receptor proteins like a key into a lock. Together, ligands and their receptors trigger signaling pathways that affect cell development and function. The TNFRSF11B protein works outside of the cell membrane.

The TNFRSF11B protein and a receptor protein called RANK can each attach to a ligand called RANKL. Because RANKL can only bind to one of these proteins at a time, the TNFRSF11B protein and RANK compete with one another. When RANKL is bound to RANK, a series of chemical signals cause osteoclasts to mature and turn on. This leads to the breakdown of bone. When RANKL is bound to the TNFRSF11B protein, these chemical signals are blocked. The TNFRSF11B protein is called a "decoy" receptor protein because no chemical signals are transmitted when RANKL is attached to this protein.

By influencing the amount of RANKL that is available to bind to RANK and activate osteoclasts, the TNFRSF11B protein plays a critical role in regulating the process of bone remodeling.

Conditions referring to this gene or chromosome

Otros nombres

OCIF

OPG

osteoclastogenesis inhibitory factor

TR1

tumour necrosis factor receptor superfamily, member 11b

Related patient information and medicines

Inmunosupresión

Patient information leaflet

Inmunosupresión

Mycophenolate... Monoclonal antibodies - of which there are many ending in "mab", such as bevacizumab, rituximab and trastuzumab. Anti-TNF drugs such as etanercept Etanercept , infliximab, adalimumab, certolizumab and golimumab. (TNF stands for anti tumour necrosis factor, and some of the "mab" medicines above act against TNF, so there is some.

Medicamentos biológicos para la artritis reumatoide

Patient information leaflet

Medicamentos biológicos para la artritis reumatoide

They are made by living o... For example, some of these biological medicines block a chemical called tumour necrosis factor alpha (TNF-alpha) which plays an important role in causing inflammation in the joints. Medicines that block TNF incluyen adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab. The other biological medicines.

Hidradenitis supurativa

Patient information leaflet

Hidradenitis supurativa

Hidradenitis supurativa es un long-term (chronic) piel condition that leads to painful and repeated lumps of pus (boils or abscesses). Hidradenitis suppurativa tends to run in families; about one-third of people with hidradenitis suppurative have a family member who is affected. The most promising of these treatments are monoclonal antibodies,.

Espondiloartritis axial

Patient information leaflet

Espondiloartritis axial

Biological medicines Biologics can be used to control the disease process. The main ones used for axial spondyloarthritis are called tumour necrosis factor (TNF) inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab or infliximab). Other medicines, such as secukinumab, bimekizumab or ixekizumab, may be used if TNF inhibitors have been.

Espondilitis anquilosante

Patient information leaflet

Espondilitis anquilosante

In ankylosing spondylitis, a chemical called cytokine tumour necrosis factor alpha (TNF-alpha) is involved in causing inflammation. Certain medicines in a group called TNF-alpha inhibitors... TNF-alpha inhibitors are also sometimes called anti-TNF-alpha drugs. In the UK the National Institute for Health and Care Excellence (NICE) recommends that.

Síndrome de Marfan

Patient information leaflet

Síndrome de Marfan

The following lists the most common problems and symptoms that may develop. Treatments are available for most of these problems. It can also cause head... What causes Marfan syndrome. Marfan syndrome is caused by a change (mutation) in el genetic material on one of tu chromosomes (chromosome number 15). The gene that is affected is responsible.

Lecturas adicionales y referencias

Historial del artículo

La información en esta página está escrita y revisada por pares por clínicos calificados.
  • 20 Nov 2025 | Última versión
  • 1 Nov 2025 | Publicado originalmente

Únete a la conversación

Comparte tus pensamientos o experiencias con otros en nuestro comunidades de pacientes.

Aviso legal: The views expressed in the community do not represent medical advice. For any health concerns, consult your GP or healthcare provider.

Farmacia en línea, tratamientos y servicios de salud

Acceso sencillo a tratamientos y servicios de salud confiables en línea.

Common conditions

Get help with common conditions through the NHS, without a GP appointment.

Book your free Pharmacy First appointment

Suscríbete al boletín de Patient

Tu dosis semanal de consejos de salud claros y confiables, escritos para ayudarte a sentirte informado, seguro y en control.

Por favor, introduce una dirección de correo electrónico válida

Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.